Raymond James Financial Services Advisors Inc. Takes Position in Genelux Co. (NASDAQ:GNLX)

Raymond James Financial Services Advisors Inc. bought a new stake in Genelux Co. (NASDAQ:GNLX) in the 4th quarter, Holdings Channel.com reports. The fund bought 13,627 shares of the company’s stock, valued at approximately $191,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Amalgamated Bank increased its stake in shares of Genelux by 250.8% in the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock valued at $26,000 after buying an additional 770 shares during the period. Exchange Traded Concepts LLC grew its stake in shares of Genelux by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock worth $87,000 after purchasing an additional 1,573 shares during the period. Falcon Wealth Planning grew its stake in shares of Genelux by 20.0% during the fourth quarter. Falcon Wealth Planning now owns 12,000 shares of the company’s stock worth $168,000 after purchasing an additional 2,000 shares during the period. New York State Common Retirement Fund grew its stake in shares of Genelux by 89.5% during the third quarter. New York State Common Retirement Fund now owns 5,495 shares of the company’s stock worth $135,000 after purchasing an additional 2,595 shares during the period. Finally, Barclays PLC grew its stake in shares of Genelux by 516.4% during the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock worth $83,000 after purchasing an additional 2,835 shares during the period. 37.33% of the stock is owned by institutional investors and hedge funds.

Genelux Trading Down 0.9 %

GNLX stock opened at $3.45 on Thursday. The business’s 50-day moving average price is $5.86 and its two-hundred day moving average price is $10.95. Genelux Co. has a 1-year low of $3.26 and a 1-year high of $40.98.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Friday, March 29th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). As a group, analysts expect that Genelux Co. will post -0.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on GNLX shares. Benchmark reaffirmed a “speculative buy” rating and set a $30.00 price objective on shares of Genelux in a research note on Wednesday, April 3rd. HC Wainwright decreased their price objective on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday, April 2nd.

Insider Activity

In other news, major shareholder Aladar Szalay sold 14,331 shares of the business’s stock in a transaction dated Monday, April 22nd. The stock was sold at an average price of $3.53, for a total value of $50,588.43. Following the sale, the insider now directly owns 1,285,794 shares in the company, valued at $4,538,852.82. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 71,078 shares of company stock worth $250,663 over the last three months. Corporate insiders own 11.70% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.